NIH grants accreditation to immunoseb, probioseb CSC3 effective supplements to resolve ‘long COVID’ fatigue symptoms
A panel of experts set up by the NIH recently published a fact sheet, which endorsed the fact that there is satisfactory clinical trial data to substantiate that ImmunoSEB and ProbioSEB CSC3 supplements are effective to moderate and resolve post-COVID fatigue and muscle weakness
The National Institutes of Health (NIH) has granted an in-principle accreditation to systemic enzyme and probiotic supplements—ImmunoSEB and ProbioSEB CSC3 for its proven clinical efficacy to resolve ‘Long-COVID’ fatigue symptoms, NIH said in a statement.
Advanced Enzyme Technologies is one of the global innovators of the ImmunoSEB and ProbioSEB CSC3 molecules, the statement added.
Further, the statement mentioned that a panel of experts set up by the NIH recently published a fact sheet, which endorsed the fact that there is satisfactory clinical trial data to substantiate that ImmunoSEB and ProbioSEB CSC3 supplements are effective to moderate and resolve post-COVID fatigue and muscle weakness.
According to NIH, ImmunoSEB and ProbioSEB CSC3 supplements administered during clinical trials conducted on 200 adults with post-COVID fatigue and muscle weakness were proven to be effective after 14-days of treatment. It was also found that fatigue resolved among 91 per cent individuals who consumed the enzyme and probiotic supplements for 14 days.
“The recently published NIH fact sheet vindicates our clinical innovation ability to resolve ‘Long-COVID’ induced fatigue symptoms. We are one of the global innovators to develop systemic enzyme and probiotic supplements, averred Dr Abhijit K Rathi, Principal Scientist, AETL.
- Advertisement -